Matches in SemOpenAlex for { <https://semopenalex.org/work/W2532874611> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2532874611 abstract "Abstract Objective: Tacrolimus, a commonly used potent immunosuppressive drug in hematopoetic stem cell transplantation (SCT), has large individual variation in concentrations and a relatively narrow therapeutic range. It is metabolized mainly by cytochrome P450 (CYP) 3A which has genetic polymorphisms influencing enzymatic activities; CYP3A5*1 and *3 genotypes represent expressor and non-expressor, respectively. In the present study, we investigated whether the tacrolimus concentration per dose is associated with CYP3A5 gene polymorphisms. Methods: 51 Japanese SCT patients (21 AML, 12 ALL, 9 CML, 3 NHL, 1 HL, 2 ATL, 1 MM, 2 AA), receiving tacrolimus were studied. DNA was extracted from peripheral blood samples. CYP3A5 genotype was analyzed by PCR-restriction fragment length polymorphism (RFLP) using specific primers and a restriction enzyme, SspI. Blood tacrolimus concentrations were measured twice a week by a commercially available EIA kit. Results: The frequency of the CYP3A5 *1/*1, *1/*3 and *3/*3 genotype was 7.8, 31.4, and 60.8% of 51 patients, respectively, and the genotype distribution was not different significantly from that of 121 Japanese healthy volunteers (2.5, 38.8, and 58.8%, respectively). The frequency of CYP3A5 genotypes of white Americans is reported to be 2.2, 12.0 and 86.0%, respectively, indicating the ethnic difference of distribution. The dose-adjusted concentrations of tacrolimus 5 to 7 days following SCT were significantly higher in CYP3A5 *3/*3 patients than in CYP3A5 *1/*1 and *1/*3 patients (691.7±298.0 ng/ml per mg/kg vs. 451.8±153.8 ng/ml per mg/kg, P=0.0017). The dose needed to achieve the target concentration (10 to 15 ng/ml) between 40 to 60 days following SCT, when the blood concentrations of tacrolimus tended to be stable in most patients, is significantly lower in CYP3A5 *3/*3 patients than in CYP3A5 *1/*1 and *1/*3 patients (0.008±0.005 mg/kg vs.0.016±0.006 mg/kg, P<0.001). Above grade two adverse events related to tacrolimus were observed only in CYP3A5 *3/*3 patients (3 patients in grade 4 and 1 patient in grade2), suggesting the contribution of a higher concentration to renal toxicity by tacrolimus. Conclusion: The tacrolimus concentration per dose in SCT patients is influenced by the CYP3A5 gene polymorphism. This is the first report showing the relationship between CYP3A5 gene polymorphism and the tacrolimus concentration in SCT patients to the best of our knowledge. Information of CYP3A5 genotype may be helpful to determine the initial tacrolimus dose adequate for each patient." @default.
- W2532874611 created "2016-10-28" @default.
- W2532874611 creator A5004999383 @default.
- W2532874611 creator A5007888883 @default.
- W2532874611 creator A5015730300 @default.
- W2532874611 creator A5020985742 @default.
- W2532874611 creator A5034892457 @default.
- W2532874611 creator A5038192500 @default.
- W2532874611 creator A5054033361 @default.
- W2532874611 creator A5054830507 @default.
- W2532874611 creator A5055166332 @default.
- W2532874611 creator A5063759141 @default.
- W2532874611 creator A5073710439 @default.
- W2532874611 creator A5080530083 @default.
- W2532874611 creator A5087583944 @default.
- W2532874611 creator A5091074660 @default.
- W2532874611 date "2006-11-16" @default.
- W2532874611 modified "2023-09-28" @default.
- W2532874611 title "Tacrolimus Concentrations in Hematopoetic Stem Cell Transplantation Patients Are Related to Cytochrome P450 3A5 Gene Polymorphisms." @default.
- W2532874611 doi "https://doi.org/10.1182/blood.v108.11.2902.2902" @default.
- W2532874611 hasPublicationYear "2006" @default.
- W2532874611 type Work @default.
- W2532874611 sameAs 2532874611 @default.
- W2532874611 citedByCount "0" @default.
- W2532874611 crossrefType "journal-article" @default.
- W2532874611 hasAuthorship W2532874611A5004999383 @default.
- W2532874611 hasAuthorship W2532874611A5007888883 @default.
- W2532874611 hasAuthorship W2532874611A5015730300 @default.
- W2532874611 hasAuthorship W2532874611A5020985742 @default.
- W2532874611 hasAuthorship W2532874611A5034892457 @default.
- W2532874611 hasAuthorship W2532874611A5038192500 @default.
- W2532874611 hasAuthorship W2532874611A5054033361 @default.
- W2532874611 hasAuthorship W2532874611A5054830507 @default.
- W2532874611 hasAuthorship W2532874611A5055166332 @default.
- W2532874611 hasAuthorship W2532874611A5063759141 @default.
- W2532874611 hasAuthorship W2532874611A5073710439 @default.
- W2532874611 hasAuthorship W2532874611A5080530083 @default.
- W2532874611 hasAuthorship W2532874611A5087583944 @default.
- W2532874611 hasAuthorship W2532874611A5091074660 @default.
- W2532874611 hasConcept C104317684 @default.
- W2532874611 hasConcept C109650736 @default.
- W2532874611 hasConcept C126322002 @default.
- W2532874611 hasConcept C135763542 @default.
- W2532874611 hasConcept C168007829 @default.
- W2532874611 hasConcept C2909675724 @default.
- W2532874611 hasConcept C2911091166 @default.
- W2532874611 hasConcept C526171541 @default.
- W2532874611 hasConcept C54355233 @default.
- W2532874611 hasConcept C62231903 @default.
- W2532874611 hasConcept C71924100 @default.
- W2532874611 hasConcept C86803240 @default.
- W2532874611 hasConcept C90924648 @default.
- W2532874611 hasConcept C92137452 @default.
- W2532874611 hasConceptScore W2532874611C104317684 @default.
- W2532874611 hasConceptScore W2532874611C109650736 @default.
- W2532874611 hasConceptScore W2532874611C126322002 @default.
- W2532874611 hasConceptScore W2532874611C135763542 @default.
- W2532874611 hasConceptScore W2532874611C168007829 @default.
- W2532874611 hasConceptScore W2532874611C2909675724 @default.
- W2532874611 hasConceptScore W2532874611C2911091166 @default.
- W2532874611 hasConceptScore W2532874611C526171541 @default.
- W2532874611 hasConceptScore W2532874611C54355233 @default.
- W2532874611 hasConceptScore W2532874611C62231903 @default.
- W2532874611 hasConceptScore W2532874611C71924100 @default.
- W2532874611 hasConceptScore W2532874611C86803240 @default.
- W2532874611 hasConceptScore W2532874611C90924648 @default.
- W2532874611 hasConceptScore W2532874611C92137452 @default.
- W2532874611 hasLocation W25328746111 @default.
- W2532874611 hasOpenAccess W2532874611 @default.
- W2532874611 hasPrimaryLocation W25328746111 @default.
- W2532874611 hasRelatedWork W1847079687 @default.
- W2532874611 hasRelatedWork W1890529144 @default.
- W2532874611 hasRelatedWork W1987600922 @default.
- W2532874611 hasRelatedWork W2357826186 @default.
- W2532874611 hasRelatedWork W2376201812 @default.
- W2532874611 hasRelatedWork W2412483522 @default.
- W2532874611 hasRelatedWork W2532874611 @default.
- W2532874611 hasRelatedWork W2581036173 @default.
- W2532874611 hasRelatedWork W3032823707 @default.
- W2532874611 hasRelatedWork W3036005157 @default.
- W2532874611 isParatext "false" @default.
- W2532874611 isRetracted "false" @default.
- W2532874611 magId "2532874611" @default.
- W2532874611 workType "article" @default.